Outlook for Pharmaceutical Continuous Manufacturing Market: Key Developments and Future Strategies to 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Estimated Industry Valuation for the Pharmaceutical Continuous Manufacturing Sector?
The market size for human raw materials in cell therapy has been expanding rapidly over the last few years. It is expected to expand from $2.82 billion in 2024 to $3.36 billion in 2025, showcasing a compound annual growth rate (CAGR) of 19.3%. This significant growth during the historic period can be credited to numerous factors, including the rising occurrence of chronic diseases, the increase in the elderly population, heightened demand for regenerative treatments, substantial governmental backing and funding, and the expansion of healthcare expenditure.
There is anticipation for the cell therapy human raw materials market to grow quickly over the forthcoming years. Predictions are for it to expand to “$6.67 billion in 2029 with a compound annual growth rate (CAGR) of 18.7%.” The expected growth during the projected period could be due to factors such as broader therapeutic uses, increased patient cognizance, advantageous regulatory structures, a flourishing biopharmaceutical industry, and superior manufacturing methods. The forecast period also signals major shifts towards the adoption of allogenic therapies, artificial intelligence integration, growth in off-the-shelf cell therapies, implementation of 3D bioprinting technology, and the emergence of hybrid cell therapies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15759&type=smp
What Forces Are Driving The Growth Of The Pharmaceutical Continuous Manufacturing Market?
The proliferation of various long-term diseases is projected to boost the advancement of the pharmaceutical continuous manufacturing market in the future. These chronic diseases, typically defined as conditions lasting for at least a year, requiring ongoing medical care and affecting daily activities, serve as a primary driver. Continuous manufacturing methods aid pharmaceutical firms in optimizing the production of medications, leading to improved efficiency and reduced expenses. Access to essential medicines is also broadened, crucial for managing chronic ailments necessitating long-term medication. For example, an April 2022 report from the National Association of Chronic Disease Directors (NACDD), a non-profit Public Health organization in the US committed to chronic disease initiatives, stated that nearly 60% of American adults have a minimum of one chronic disease. Around 40% of American adults have multiple chronic conditions (MCC), which are anticipated to cost the US economy $2 trillion every year, or $8,600 per person by 2030. As a result, the escalating occurrence of numerous chronic diseases will fuel the growth of the pharmaceutical continuous manufacturing market.
The cell therapy human raw materials market covered in this report is segmented –
1) By Product: Cell Culture Media, Cell Culture Sera, Cell Culture Supplements, Reagents And Buffers, Other Raw Materials
2) By Type Of Cell Therapy: Dendritic Cell Therapy, Natural Killer (NK) Cell Therapy, Stem Cell Therapy, T-Cell Therapy
3) By End-Use: Biopharmaceutical And Pharmaceutical Companies, Contract Research Organizations (CROs) And Contract Manufacturing Organization (CMOs), Academic And Research Institutions
Subsegments:
1) By Cell Culture Media: Serum-Free Media, Serum-Based Media, Defined Media, Specialized Media (E.G., For Stem Cells)
2) By Cell Culture Sera: Fetal Bovine Serum (FBS), Human Serum, Adult Bovine Serum
3) By Cell Culture Supplements: Growth Factors, Cytokines, Peptides
4) By Reagents And Buffers: Enzymes (E.G., Trypsin), Ph Buffers, Cryoprotectants
5) By Other Raw Materials: Cell-Free DNA, Plasma And Platelet-Rich Plasma (PRP), Vials And Storage Containers
What Trends Are Currently Influencing Growth In The Pharmaceutical Continuous Manufacturing Market?
Forefront companies in the cell therapy human raw materials market are increasingly prioritizing the creation of chemically defined cell culture mediums to expedite cell therapy development. A cell culture medium is a nourishment-laden solution devised to offer vital nutrients, growth stimulants, and essential environmental conditions for the in vitro growth and propagation of cells outside their original habitat. For instance, in May 2023, a healthcare manufacturing firm based in Switzerland known as Lonza Group AG, unveiled its TheraPEAK T-VIVO Cell Culture Medium. This novel introduction includes a chemically defined formulation, devoid of serum and animal components, recombinant proteins, elevated culture support, and expansion assistance as well as application aid to ensure continual consistency, safety, and adherence to regulatory standards in cell therapy manufacturing. The significant technological progress this medium represents is marked by the elimination of animal components, chemically defined formulation, and its ability to remain regulatory-friendly. These contribute to an enhanced level of safety, quality, and regulatory compliance.
Which Companies Currently Dominate The Competitive Landscape In The Pharmaceutical Continuous Manufacturing Industry?
Major companies operating in the cell therapy human raw materials market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, GE Healthcare, Corning Incorporated, Lonza Group Ltd., Grifols S.A., WuXi AppTec, Catalent Inc., Sartorius AG, Charles River Laboratories, Bio-Rad Laboratories Inc., Pall Corporation, Bio-Techne Corporation, Miltenyi Biotec, Actylis, STEMCELL Technologies, Takara Bio Inc., Vericel Corporation, ACROBiosystems, BioIVT LLC, Orgenesis Inc., PromoCell GMBH, ViaCyte Inc., AllCells LLC, Sartorius CellGenix GmbH, Fujifilm Cellular Dynamics Inc., Mesoblast Limited, RoosterBio Inc., Thermogenesis Holdings Inc.
Which Geographic Regions Are Driving Demand In The Pharmaceutical Continuous Manufacturing Market?
North America was the largest region in the cell therapy human raw materials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell therapy human raw materials market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=15759&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
